Best of WCLC 2025 Webinar-Best of WCLC 2025 Recording

Video Transcription

Video Summary

The ICLC Webinar showcased cutting-edge lung cancer research from leading experts. Dr. Myung Joon Eun presented the phase II ID8Lung01 trial evaluating IDXD, an antibody-drug conjugate (ADC), in pretreated extensive small cell lung cancer (SCLC). With a 48.2% objective response rate (ORR), including brain metastasis patients, IDXD showed promising efficacy and manageable safety. Dr. Sanja Desik discussed AI-based machine learning algorithms facilitating precise, standardized pathological assessments of neoadjuvant treatment response, reducing inter-observer variability and expediting diagnostic turnaround times. Dr. Lauren Byers introduced ABBV706, an SES-6 targeting ADC for relapsed/refractory SCLC showing rapid, high response rates (up to 77% in second-line) and manageable toxicity, supporting ongoing development. Dr. Catherine Xu presented SKYSCRAPER-05, a phase II study of perioperative tiragolumab (anti-TIGIT) with atezolizumab ± chemotherapy in resectable locally advanced NSCLC. The trial demonstrated high surgical feasibility with major pathologic responses across PD-L1 subgroups and acceptable safety. Panel discussions highlighted challenges translating trial results to real-world settings, emphasized patient selection, and discussed the potential and limitations of novel immunotherapies. Overall, these presentations reflect significant advances in targeted therapies, immunotherapy combinations, and integration of AI in lung cancer management, promising improved outcomes for diverse patient populations.

Keywords

lung cancer

small cell lung cancer

IDXD antibody-drug conjugate

AI machine learning pathology

ABBV706 SES-6 targeting ADC

tiragolumab anti-TIGIT

atezolizumab chemotherapy

neoadjuvant treatment response

immunotherapy advances